| 107.97 27.2 (33.68%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 130.05 |
1-year : | 151.9 |
| Resists | First : | 111.34 |
Second : | 130.05 |
| Pivot price | 80.41 |
|||
| Supports | First : | 83.93 |
Second : | 66.98 |
| MAs | MA(5) : | 83.93 |
MA(20) : | 80.37 |
| MA(100) : | 69.07 |
MA(250) : | 73.76 |
|
| MACD | MACD : | 3.5 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 50.4 |
| RSI | RSI(14): 81 |
|||
| 52-week | High : | 118.83 | Low : | 41.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GRAL ] has closed It is unclear right now based on current values. 114.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 111.48 - 111.91 | 111.91 - 112.34 |
| Low: | 97.63 - 98.1 | 98.1 - 98.57 |
| Close: | 107.16 - 107.93 | 107.93 - 108.7 |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Tue, 22 Sep 2026
GRAIL, Inc. stock surges 33% to $107.97, but RSI hits 81 ahead of FDA call - The Cryptonomist
Mon, 21 Sep 2026
GRAL Stock Breaks Out As Traders Eye Fresh Momentum - timothysykes.com
Mon, 21 Sep 2026
GRAL Stock Roars Higher As Traders Target Breakout Momentum - StocksToTrade
Mon, 21 Sep 2026
Up to $5.8M in insider stock may be sold at GRAIL, Inc. (GRAL) - Stock Titan
Mon, 21 Sep 2026
GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade) - Seeking Alpha
Mon, 21 Sep 2026
Why Is Grail Stock Surging Today? - GRAIL (NASDAQ:GRAL) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 45 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 8,160 (K) |
| Shares Short P.Month | 7,730 (K) |
| EPS | -9.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 56.93 |
| Profit Margin | -237 % |
| Operating Margin | -332 % |
| Return on Assets (ttm) | -12.1 % |
| Return on Equity (ttm) | -16.2 % |
| Qtrly Rev. Growth | 25.7 % |
| Gross Profit (p.s.) | 1.83 |
| Sales Per Share | 3.69 |
| EBITDA (p.s.) | -8.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -295 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -11.15 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 29.18 |
| Price to Cash Flow | -16.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|